1-10 of 10
Ahmed Hamed Salem, PhD FCP
Close
Sort by
Journal Articles

Venetoclax Crosses the Blood Brain Barrier: A Pharmacokinetic Analysis of the Cerebrospinal Fluid in Pediatric Leukemia Patients

Ahmed Hamed Salem, PhD FCP, Mohamed A Badawi, PhD, Andrew E. Place, MDPhD, Tammy L. Palenski, PhD, Richard Arrendale, PhD, Su Young Kim, Sara Federico, MD, Todd M. Cooper, DO, Rajeev Menon, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-137197
Published: 2020
Journal Articles

Venetoclax Exposure-Efficacy and Exposure-Safety Relationships in Subjects with Treatment-Naïve Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Doerthe Eckert, MSc, Deanna Brackman, PhD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP, Jalaja Potluri, MD, B. Douglas Smith, MD, Andrew H. Wei, John Hayslip, MD MSCR, Dale Miles, PhD, Sven Mensing, PhD, Sathej Gopalakrishnan, PhD, Jiuhong Zha, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52.
https://doi.org/10.1182/blood-2020-136425
Published: 2020
Journal Articles

Proposed Scheme for Dosing Venetoclax in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships

Mohamed A Badawi, PhD, Sathej Gopalakrishnan, PhD, Benjamin Engelhardt, PhD, Tammy L. Palenski, PhD, Su Young Kim, Seth E. Karol, MD, Jeffrey E. Rubnitz, MD, Rajeev Menon, PhD, Ahmed Hamed Salem, PhD FCP
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-139593
Published: 2020
Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

Amer M. Zeidan, MBBS, MHS, Daniel A Pollyea, MD, Jacqueline S Garcia, MD, Andrew Brunner, MD, Fernando Roncolato, BMed, FRACP, FRCPA, Uma Borate, MD, Olatoyosi Odenike, MD, Ashish R. Bajel, FRACP, Anne Marie Watson, FRACP, FRCPA, MBBS, Katharina Götze, Florian Nolte, MD, Peter T. Tan, MBBS, Wan-Jen Hong, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Lori Gressick, BS, William Ainsworth, PhD, Jason Harb, PhD, Ahmed Hamed Salem, PhD FCP, John Hayslip, Ronan Swords, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 565.
https://doi.org/10.1182/blood-2019-124994
Published: 2019
Journal Articles

Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Norman J. Lacayo, MD, Vinod A. Pullarkat, MD, Wendy Stock, MD, Elias Jabbour, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Jeffrey Rubnitz, MD PhD, Jessica Leonard, MD, Charles G. Mullighan, MBBS, MD, Seong Lin Khaw, MD, Susan I. Vear, MD MSCI, Joseph T. Opferman, PhD, Ahmed Hamed Salem, PhD FCP, Michelle Schmidt, Bo Tong, PhD, Lang Zhou, PhD, Jeremy A. Ross, PhD, Lindsey Bensman, Amanda Jacobson, PhD, Robin Norris, MD MS, MPH, Thomas Alexander, MDMPH
Journal: Blood
Blood (2019) 134 (Supplement_1): 285.
https://doi.org/10.1182/blood-2019-126977
Published: 2019
Journal Articles

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid Leukemia

Seth E Karol, MD, Thomas Alexander, MDMPH, Amit Budraja, PhD, Stanley Pounds, PhD, Kristin E Canavera, PhD, Lei Wang, MS, Joshua Wolf, MBBS, PhD, Jeffery M. Klco, MD PhD, Ahmed Hamed Salem, PhD FCP, Tammy Palenski, PhD, Norman J. Lacayo, MD, Ching-Hon Pui, MD, Joseph T. Opferman, PhD, Jeffrey Rubnitz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 178.
https://doi.org/10.1182/blood-2019-127716
Published: 2019
Journal Articles

Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Phase 1 Study

Seth E Karol, MD, Todd M Cooper, DO, Henrique Bittencourt, Lia Gore, MD, Maureen M O'Brien, MD, Christopher Fraser, MD, Marion Gambart, MD, Gunnar Cario, MD PhD, Christian Michel Zwaan, MD PhD, Jean-Pierre Bourquin, MD PhD, Mignon L. Loh, MD, Hubert Caron, MD PhD, Betty Prine, Ahmed Hamed Salem, PhD FCP, Kristina Unnebrink, Bo Tong, PhD, Tammy Palenski, PhD, Andrew E. Place, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2649.
https://doi.org/10.1182/blood-2019-129805
Published: 2019
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Constantine S. Tam, MBBS, MD, Tanya Siddiqi, MD, John N. Allan, MD, Thomas J. Kipps, MD PhD, Ian W. Flinn, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Stephen Opat, Paul M. Barr, MD, Alessandra Tedeschi, MD, Ryan Jacobs, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Paolo Ghia, MD PhD, Juthamas Sukbuntherng, PhD, Ahmed Hamed Salem, PhD FCP, Kristin Russell, BS, Karl Eckert, BA, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 35.
https://doi.org/10.1182/blood-2019-121424
Published: 2019
Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 925.
https://doi.org/10.1182/blood-2019-124407
Published: 2019
Journal Articles

Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina Gasparetto, MD, Fredrik H. Schjesvold, MD PhD, Philippe Moreau, MD, Cyrille Touzeau, MD, Thierry Facon, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Tammy Macartney, John Pesko, PhD, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, Wan-Jen Hong, MD, Paulo C. Maciag, MD PhD, James M. Pauff, MD PhD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 926.
https://doi.org/10.1182/blood-2019-125871
Published: 2019